S&P Futures
4,253.50 -33.00 (-0.77%) Dow Futures
33,782.00 -199.00 (-0.59%) Nasdaq Futures
13,390.50 -132.75 (-0.98%) Russell 2000 Futures
1,983.00 -18.70 (-0.93%) Crude Oil
89.20 -1.30 (-1.44%) Gold
1,767.30 -3.90 (-0.22%)
CytomX Therapeutics, Inc. (CTMX)
Pre-Market:
Chart Events
Performance Outlook
| Previous Close | 1.6300 |
| Open | 1.6400 |
| Bid | 0.0000 x 3000 |
| Ask | 0.0000 x 3000 |
| Day's Range | 1.6050 - 1.6800 |
| 52 Week Range | 1.1900 - 7.5300 |
| Volume | |
| Avg. Volume | 1,900,813 |
| Market Cap | 108.818M |
| Beta (5Y Monthly) | 0.48 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.4090 |
| Earnings Date | Nov 02, 2022 - Nov 07, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.41 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for CTMX
Related Research
- CytomX Therapeutics, Inc.The Argus High-Yield Model PortfolioValue stocks -- a market segment that includes high-yield stocks -- are outperforming growth stocks in 2022 for the first time since 2016. Indeed, for the past decade, the performance record has favored growth. In nine of the past 10 years, growth stocks have topped value stocks. But the tide may be turning. The rollout of COVID-19 vaccines has given a lift to some of the cyclical companies (energy companies and regional banks) that have lagged in recent quarters, and value stocks have kept up the pace with growth stocks in the past year. Now, the Federal Reserve lifting interest rates to fend off inflation, which will likely cap multiple expansion for growth companies. Regardless, the value sector is the place to achieve income. The current yield on the iShares Russell 1000 Value Index ETF is 2.1%, compared to the 0.8% current yield on the iShares Russell 1000 Growth Index ETF. For our High-Yield Theme Model Portfolio, we are seeking stocks with yields of at least 3.0%. This moves us deep into the value segment of the market.RatingFair ValueEconomic Moat13 hours agoArgus Research
- Motley Fool
CytomX Therapeutics (CTMX) Q2 2022 Earnings Call Transcript
Before we begin, I'd like to remind everyone that during this call, we will be making forward-looking statements. Because forward-looking statements relate to the future, they are subject to inherent uncertainties and risks that are difficult to predict and many of which are outside of our control.
- Zacks
CytomX Therapeutics (CTMX) Reports Q2 Loss, Lags Revenue Estimates
CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of -2.78% and 1.42%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
CytomX Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update
- Recently-announced company restructuring focuses internal efforts on wholly-owned next-generation conditionally activated therapeutics, extending cash runway to 2025 - - New INDs for two next-generation product candidates anticipated in 2023 - - Continued progress with partnered clinical programs: CX-904 (Amgen, Phase 1), BMS-986249 (Bristol Myers Squibb, Phase 2), and CX-2029 (AbbVie, Phase 2) - SOUTH SAN FRANCISCO, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:
